Absolute Clinical Research LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$3,756	2
2024	Research	$12,671	5
2023	Research	$21,510	6
2022	Research	$64,091	1

Breakdown

Who paid Research payments · program years 2022–2025

Otsuka Pharmaceutical Development & Commercialization, Inc. $69,070 3 payments
Exact Sciences Corporation $31,707 10 payments
Sumitomo Pharma America, Inc. $1,250 1 payment

Studies the money was for Research payments · program years 2022–2025

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury (Tbi) $69,070 3 payments
Informed Choice Intervention for Colorectal Cancer Screening - COMPASS $16,530 4 payments
Informed Choice Intervention for Colorectal Cancer Screening $11,421 4 payments
Informed Choice Intervention for Colorectal Cancer Screening: COMPASS $3,250 1 payment
A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder $1,250 1 payment
Informed Choice Intervention for Colorectal Cancer Screening: COMPASS $506 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.